Skip to main content
. 2025 May 21;51(2):e20240416. doi: 10.36416/1806-3756/e20240416

Table 2. Psychosocial outcomes in the study population, by sex.a .

Total sample (N = 218) Males (n = 101) Females (n = 117) p
Depression at T1, PHQ-9 19.1%; 95% CI, 14.4-24.8 11.0%; 95% CI, 6.2-18.6 26.1%; 95% CI, 18.9-34.8 0.005*
Depression at T1, PHQ-9 4 [0-23] 3 [0-22] 5 [0-21] 0.03**
Depression at T2, PHQ-9 15.4%; 95% CI, 11.1-20.9 9.3%; 95% CI, 5.0-16.7 20.7%; 95% CI, 14.2-29.2 0.02*
Depression at T2, PHQ-9 3 [0-24] 3 [0-24] 3 [0-24] 0.46**
Anxiety at T1, GAD-7 scale 19.1%; 95% CI, 14.4-24.8 12.0%; 95% CI, 7.0-19.8 25.2%; 95% CI, 18.2-33.9 0.014*
Anxiety at T1, GAD-7 scale 4 [0-20] 3 [0-20] 6 [0-20] 0.005**
Anxiety at T2, GAD-7 scale 18.0%; 95% CI, 13.4-23.7 10.2%; 95% CI, 5.6-17.8 24.8%; 95% CI, 17.7-33.5 0.006*
Anxiety at T2, GAD-7 scale 4 [0-20] 3 [0-19] 5 [0-20] 0.06**
Treatment adherence, MMAS-8
High
Average
Low

5.3%; 95% CI, 2.6-10.5
28.0%; 95% CI, 21.2-36.2
66.7%; 95% CI, 58.2-74.1

6.8%; 95% CI, 2.7-16.2
28.8%; 95% CI, 18.6-41.4
64.4%; 95% CI, 51.7-75.4

4.1%; 95% CI, 1.4-11.4
27.4%; 95% CI, 1.5-38.6
68.5; 95% CI, 57.1-78
0.54*
Treatment adherence, MMAS-8 5 [0-8] 5 [1-8] 5 [0-8] 0.93**

T1: time point 1; T2: time point 2; PHQ-9: nine-item Patient Health Questionnaire; GAD-7: seven-item Generalized Anxiety Disorder; and MMAS-8: eight-item Morisky Medication Adherence Scale. aData expressed as % or median [IQR]. *Chi-square test (p < 0.05). **Mann-Whitney test (p < 0.05).